Research Focus: GHRH Signaling · Growth Hormone Axis · Endocrine & Metabolic Research
Compound Class: Growth Hormone-Releasing Hormone (GHRH) Analog
Mechanism of Action
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to activate the GHRH receptor (GHRH-R) and stimulate the endogenous growth hormone (GH) signaling axis.
At the molecular level, tesamorelin binds GHRH receptors expressed on pituitary somatotroph cells. GHRH-R belongs to the class B family of G protein-coupled receptors. Receptor activation primarily stimulates Gs proteins, increasing adenylyl cyclase activity and intracellular cyclic adenosine monophosphate (cAMP).
The resulting cAMP-dependent signaling activates downstream pathways that regulate synthesis and secretion of growth hormone from pituitary somatotrophs.
Growth hormone subsequently interacts with the growth hormone receptor (GHR) in peripheral tissues and stimulates downstream signaling, including production of insulin-like growth factor-1 (IGF-1), forming the interconnected GHRH → GHRH-R → GH → GHR → IGF-1 axis.
Unlike direct exposure to exogenous growth hormone, GHRH receptor agonism acts upstream at the pituitary level. Tesamorelin is therefore an important research compound for investigating regulation of endogenous GH secretion.
Product Overview
Tesamorelin 10 mg is a synthetic GHRH analog consisting of the 44-amino-acid sequence of human GHRH with a modification at the N-terminus that increases stability relative to endogenous GHRH.
Natural GHRH is produced primarily within the hypothalamus and acts on the anterior pituitary to regulate pulsatile GH secretion. Endogenous GHRH is rapidly degraded, which limits its duration of biological activity. Tesamorelin was developed to retain GHRH receptor activity while providing greater resistance to enzymatic degradation.
The compound has been extensively characterized in human research and is particularly useful for studying the hypothalamic-pituitary growth hormone axis, IGF-1 signaling, lipid metabolism and adipose tissue biology.
Primary Biological Targets & Pathways
- Growth hormone-releasing hormone receptor (GHRH-R)
- Pituitary somatotroph cells
- Gs protein signaling
- Adenylyl cyclase
- cAMP signaling
- Protein kinase A (PKA)-associated signaling
- Growth hormone secretion
- Growth hormone receptor signaling
- IGF-1 production
- GH/IGF-1 endocrine axis
- Lipid metabolism
- Adipose tissue biology
Primary Research Applications
Tesamorelin has been investigated in research involving:
- GHRH receptor pharmacology
- Growth hormone physiology
- GH/IGF-1 signaling
- Hypothalamic-pituitary regulation
- Endocrine signaling
- Visceral adipose tissue biology
- Lipid metabolism
- Hepatic lipid metabolism
- Metabolic physiology
- Growth hormone secretagogue research
- Age-associated endocrine signaling
Scientific Evidence
Evidence Level: ★★★★★ (5 of 5)
Tesamorelin has substantially stronger human evidence than most compounds commonly categorized as research peptides. Its mechanism has been evaluated through controlled clinical studies, and tesamorelin is an FDA-approved active pharmaceutical ingredient for specific medical indications.
Clinical research has established activation of the endogenous GH/IGF-1 axis and has extensively characterized changes associated with GHRH receptor agonism.
Importantly, FDA approval of a pharmaceutical product containing tesamorelin does not mean that independently marketed research-grade tesamorelin products are themselves FDA-approved drugs.
Research Highlights
Published research has established that tesamorelin:
- Functions as an agonist of the GHRH receptor.
- Activates pituitary signaling responsible for endogenous GH secretion.
- Produces downstream changes in the GH/IGF-1 endocrine axis.
- Provides a model for investigating GHRH-mediated endocrine regulation.
- Preserves upstream regulation of GH signaling rather than functioning as exogenous recombinant growth hormone.
Tesamorelin vs. CJC-1295
Although both compounds are associated with GHRH signaling, they should not be presented as identical. Tesamorelin is a synthetic GHRH analog with extensive controlled human research and is an FDA-approved active ingredient for specific indications. CJC-1295 is a modified GHRH analog developed to prolong GHRH-like activity, with a different molecular structure, different pharmacokinetic characteristics and a considerably different regulatory history.
Research Use Disclaimer
For Laboratory Research Use Only.
This product is intended exclusively for scientific, analytical, and laboratory research. Information presented describes the compound’s molecular biology and findings reported in scientific literature, and should not be interpreted as instructions for administration or as expected outcomes in individuals.
This product is not intended for human consumption, therapeutic administration, diagnosis, treatment, cure, or prevention of disease.
References
- FDA prescribing information and regulatory documentation for tesamorelin.
- Falutz J, et al. Controlled clinical investigations of tesamorelin and the GH/IGF-1 axis.
- Stanley TL, et al. Clinical investigations of tesamorelin and hepatic lipid metabolism.
- Grinspoon SK, et al. Research examining GHRH analog signaling and metabolic physiology.
- Peer-reviewed literature examining GHRH receptor pharmacology and hypothalamic-pituitary GH regulation.
Reviews
There are no reviews yet.